Incretin Mimetics and Amylin Analogues
INDICATIONS
FDA
FDA
- Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
- High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
- Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 3, 2021
Citation
Patel, Nisha K, et al. "Incretin Mimetics and Amylin Analogues." Johns Hopkins Diabetes Guide, 2021. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/8/Incretin_Mimetics_and_Amylin_Analogues.
Patel NK, Pherson E, Pinto B, Emiliano A. Incretin Mimetics and Amylin Analogues. Johns Hopkins Diabetes Guide. 2021. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/8/Incretin_Mimetics_and_Amylin_Analogues. Accessed November 29, 2023.
Patel, N. K., Pherson, E., Pinto, B., & Emiliano, A. (2021). Incretin Mimetics and Amylin Analogues. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/8/Incretin_Mimetics_and_Amylin_Analogues
Patel NK, Pherson E, Pinto B, Emiliano A. Incretin Mimetics and Amylin Analogues [Internet]. In: Johns Hopkins Diabetes Guide. ; 2021. [cited 2023 November 29]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/8/Incretin_Mimetics_and_Amylin_Analogues.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Incretin Mimetics and Amylin Analogues
ID - 547071
A1 - Patel,Nisha,Pharm.D.
AU - Pherson,Emily,Pharm.D.
AU - Pinto,Brian,Pharm.D.
AU - Emiliano,Ana,M.D.
Y1 - 2021/09/03/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547071/8/Incretin_Mimetics_and_Amylin_Analogues
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -